Hidetaka Kawabata

1.4k total citations
49 papers, 978 citations indexed

About

Hidetaka Kawabata is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Hidetaka Kawabata has authored 49 papers receiving a total of 978 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 18 papers in Cancer Research and 12 papers in Molecular Biology. Recurrent topics in Hidetaka Kawabata's work include Breast Cancer Treatment Studies (11 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer Treatment and Pharmacology (9 papers). Hidetaka Kawabata is often cited by papers focused on Breast Cancer Treatment Studies (11 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer Treatment and Pharmacology (9 papers). Hidetaka Kawabata collaborates with scholars based in Japan and United States. Hidetaka Kawabata's co-authors include Megumi Sato, Yuko Fujiwara, Tohru Komiya, Toshiaki Noce, Hirokazu Fujimoto, M. Furusawa, Satoshi Inoue, Kazuhiro Ikeda, Kuniko Horie‐Inoue and Takashi Suzuki and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Hidetaka Kawabata

44 papers receiving 968 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hidetaka Kawabata Japan 14 541 277 233 182 106 49 978
Oľga Østrup Denmark 18 619 1.1× 115 0.4× 216 0.9× 208 1.1× 202 1.9× 61 1.0k
Rumela Chakrabarti United States 15 597 1.1× 446 1.6× 155 0.7× 220 1.2× 86 0.8× 27 1.1k
Claudia Andreu‐Vieyra United States 21 869 1.6× 204 0.7× 256 1.1× 291 1.6× 260 2.5× 37 1.4k
Catherine Dubois d’Enghien France 13 528 1.0× 264 1.0× 177 0.8× 179 1.0× 51 0.5× 19 870
Akinori Yoda Japan 19 938 1.7× 404 1.5× 165 0.7× 173 1.0× 117 1.1× 32 1.4k
Evgeny N. Suspitsin Russia 20 511 0.9× 288 1.0× 530 2.3× 288 1.6× 36 0.3× 78 1.1k
Andrew Georgiadis United States 8 309 0.6× 144 0.5× 212 0.9× 264 1.5× 104 1.0× 13 639
Lionel Coignet France 21 530 1.0× 280 1.0× 208 0.9× 95 0.5× 138 1.3× 42 1.1k
Abdelkader Essafi United Kingdom 10 903 1.7× 144 0.5× 101 0.4× 114 0.6× 53 0.5× 11 1.2k
Margaret L. Flannery United States 11 1.1k 1.9× 258 0.9× 254 1.1× 303 1.7× 180 1.7× 12 1.6k

Countries citing papers authored by Hidetaka Kawabata

Since Specialization
Citations

This map shows the geographic impact of Hidetaka Kawabata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hidetaka Kawabata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hidetaka Kawabata more than expected).

Fields of papers citing papers by Hidetaka Kawabata

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hidetaka Kawabata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hidetaka Kawabata. The network helps show where Hidetaka Kawabata may publish in the future.

Co-authorship network of co-authors of Hidetaka Kawabata

This figure shows the co-authorship network connecting the top 25 collaborators of Hidetaka Kawabata. A scholar is included among the top collaborators of Hidetaka Kawabata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hidetaka Kawabata. Hidetaka Kawabata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ikeda, Kazuhiro, Keiichi Kinowaki, Hidetaka Kawabata, et al.. (2025). Combined use of immunoreactivities of Efp and ZCCHC3 for predicting prognosis of patients with triple‐negative breast cancer. Pathology International. 75(2). 92–99.
2.
Tamura, Nobuko, et al.. (2024). Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer. Breast Cancer. 31(6). 1018–1027. 1 indexed citations
3.
4.
Tamura, Nobuko, Yôko Kobayashi, Junichiro Sato, et al.. (2023). Abstract P5-01-02: Diagnostic Accuracy of 18F-FDG PET/CT plus Contrast-Enhanced MRI for Axillary Lymph Node Metastasis Involved in Invasive Ductal Carcinoma. Cancer Research. 83(5_Supplement). P5–1.
5.
Horie, Kuniko, Kiyoshi Takagi, Yuichi Mitobe, et al.. (2022). Estrogen-Inducible LncRNA BNAT1 Functions as a Modulator for Estrogen Receptor Signaling in Endocrine-Resistant Breast Cancer Cells. Cells. 11(22). 3610–3610. 10 indexed citations
6.
Ozaki, Yukinori, Junji Tsurutani, Toru Mukohara, et al.. (2022). Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B). European Journal of Cancer. 171. 193–202. 24 indexed citations
7.
Ozaki, Yukinori, Junji Tsurutani, Toru Mukohara, et al.. (2022). Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer. Data in Brief. 45. 108558–108558. 1 indexed citations
8.
Tamura, Nobuko, Yôko Kobayashi, Junichiro Sato, et al.. (2022). Clinical prediction model based on 18F-FDG PET/CT plus contrast-enhanced MRI for axillary lymph node macrometastasis. Frontiers in Oncology. 12. 989650–989650. 2 indexed citations
9.
Ikeda, Kazuhiro, Takashi Suzuki, Wataru Sato, et al.. (2022). PSPC1 is a potential prognostic marker for hormone-dependent breast cancer patients and modulates RNA processing of ESR1 and SCFD2. Scientific Reports. 12(1). 9495–9495. 9 indexed citations
10.
Fukada, Ippei, Yoshinori Ito, Naoto Kondo, et al.. (2021). A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17). Breast Cancer Research and Treatment. 190(3). 425–434.
11.
Mitobe, Yuichi, Kaori Iino, Ken‐ichi Takayama, et al.. (2020). PSF Promotes ER-Positive Breast Cancer Progression via Posttranscriptional Regulation of ESR1 and SCFD2. Cancer Research. 80(11). 2230–2242. 34 indexed citations
12.
13.
Tanabe, Yuko, Seiji Shiraishi, Kenji Hashimoto, et al.. (2020). Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients. BMC Cancer. 20(1). 325–325. 13 indexed citations
14.
Takahashi, Momoko, Yukinori Ozaki, Jun Masuda, et al.. (2019). Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. BMC Cancer. 19(1). 980–980. 45 indexed citations
15.
Iino, Kaori, Yuichi Mitobe, Kazuhiro Ikeda, et al.. (2019). RNA‐binding protein NONO promotes breast cancer proliferation by post‐transcriptional regulation of SKP2 and E2F8. Cancer Science. 111(1). 148–159. 64 indexed citations
16.
17.
Kikuchi, Yasuko, Yoshihiro Uchida, Kazuo Shirakawa, et al.. (2018). A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane‐based regimens. Asia-Pacific Journal of Clinical Oncology. 14(5). e231–e237. 7 indexed citations
18.
Tanioka, Maki, Akihiko Shimomura, Makoto Fujishima, et al.. (2014). Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status. The Breast. 23(4). 466–472. 23 indexed citations
19.
Miura, Daishu, et al.. (2007). Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by a rapid recruitment of natural killer cells in Her-2 overexpressing breast cancer. Journal of Clinical Oncology. 25(18_suppl). 3503–3503. 2 indexed citations
20.
Kawabata, Hidetaka, et al.. (1998). Preparation of Heat-Labile Antigens on Air-Dried Cytologic Specimens for Immunocytochemical Analysis. Acta Cytologica. 42(3). 707–715. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oľga Østrup Breakdown of academic impact, for papers by Rumela Chakrabarti Breakdown of academic impact, for papers by Claudia Andreu‐Vieyra Breakdown of academic impact, for papers by Catherine Dubois d’Enghien Breakdown of academic impact, for papers by Akinori Yoda Breakdown of academic impact, for papers by Evgeny N. Suspitsin Breakdown of academic impact, for papers by Andrew Georgiadis Breakdown of academic impact, for papers by Lionel Coignet Breakdown of academic impact, for papers by Abdelkader Essafi Breakdown of academic impact, for papers by Margaret L. Flannery
Rankless by CCL
2026